 John Marecki
Concepts (208)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA Helicases | 2 | 2021 | 29 | 1.360 |
Why?
| | Enzyme Inhibitors | 3 | 2021 | 386 | 1.210 |
Why?
| | G-Quadruplexes | 5 | 2024 | 80 | 0.840 |
Why?
| | Virus Replication | 2 | 2021 | 140 | 0.780 |
Why?
| | Superoxide Dismutase | 3 | 2013 | 114 | 0.760 |
Why?
| | Enzyme Assays | 1 | 2021 | 9 | 0.750 |
Why?
| | Saccharomyces cerevisiae Proteins | 4 | 2024 | 154 | 0.740 |
Why?
| | RNA | 2 | 2021 | 171 | 0.740 |
Why?
| | Thiobarbiturates | 1 | 2018 | 23 | 0.650 |
Why?
| | Viral Nonstructural Proteins | 1 | 2018 | 56 | 0.620 |
Why?
| | DNA Helicases | 3 | 2024 | 144 | 0.580 |
Why?
| | DEAD-box RNA Helicases | 3 | 2021 | 34 | 0.540 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 2 | 2006 | 3 | 0.540 |
Why?
| | Indoles | 1 | 2018 | 278 | 0.530 |
Why?
| | Hypertension, Pulmonary | 3 | 2007 | 121 | 0.530 |
Why?
| | Saccharomyces cerevisiae | 4 | 2024 | 189 | 0.520 |
Why?
| | Oxidative Stress | 4 | 2016 | 771 | 0.510 |
Why?
| | HIV-1 | 2 | 2006 | 55 | 0.500 |
Why?
| | Adiponectin | 2 | 2011 | 64 | 0.450 |
Why?
| | Hyperinsulinism | 1 | 2011 | 25 | 0.370 |
Why?
| | Adiposity | 1 | 2011 | 133 | 0.340 |
Why?
| | Hepacivirus | 2 | 2021 | 104 | 0.330 |
Why?
| | Simian immunodeficiency virus | 2 | 2006 | 4 | 0.330 |
Why?
| | Adipose Tissue | 1 | 2011 | 187 | 0.330 |
Why?
| | Gene Products, nef | 2 | 2007 | 2 | 0.290 |
Why?
| | DNA | 4 | 2024 | 541 | 0.280 |
Why?
| | Cell Nucleus | 2 | 2024 | 187 | 0.280 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2006 | 6 | 0.270 |
Why?
| | Pulmonary Artery | 2 | 2007 | 145 | 0.250 |
Why?
| | Gene Products, tat | 1 | 2004 | 4 | 0.240 |
Why?
| | Sp1 Transcription Factor | 1 | 2004 | 21 | 0.240 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2004 | 48 | 0.240 |
Why?
| | Lung | 3 | 2006 | 490 | 0.220 |
Why?
| | Obesity | 2 | 2011 | 1108 | 0.220 |
Why?
| | DNA, Mitochondrial | 1 | 2024 | 113 | 0.220 |
Why?
| | Ataxia Telangiectasia | 1 | 2002 | 6 | 0.210 |
Why?
| | Benzoquinones | 3 | 2006 | 29 | 0.200 |
Why?
| | Bacteriophage T4 | 1 | 2021 | 29 | 0.200 |
Why?
| | Animals | 13 | 2019 | 13246 | 0.200 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 428 | 0.190 |
Why?
| | Disease Models, Animal | 6 | 2012 | 1458 | 0.190 |
Why?
| | Structure-Activity Relationship | 2 | 2021 | 401 | 0.190 |
Why?
| | Fluorescence | 1 | 2021 | 41 | 0.190 |
Why?
| | Mitochondria | 1 | 2024 | 404 | 0.180 |
Why?
| | Transcription Factors | 1 | 2004 | 564 | 0.180 |
Why?
| | Cytoplasm | 2 | 2021 | 91 | 0.180 |
Why?
| | Viral Proteins | 1 | 2021 | 156 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 1378 | 0.170 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2019 | 13 | 0.170 |
Why?
| | Muscle Cells | 1 | 2019 | 22 | 0.170 |
Why?
| | Lymph | 1 | 2019 | 19 | 0.170 |
Why?
| | Lymphatic Vessels | 1 | 2019 | 48 | 0.160 |
Why?
| | Muscle Contraction | 1 | 2019 | 106 | 0.160 |
Why?
| | DNA, Single-Stranded | 3 | 2024 | 88 | 0.160 |
Why?
| | DNA Damage | 2 | 2021 | 301 | 0.160 |
Why?
| | Molecular Structure | 1 | 2018 | 296 | 0.150 |
Why?
| | Doxorubicin | 1 | 2019 | 239 | 0.150 |
Why?
| | Humans | 12 | 2021 | 50209 | 0.140 |
Why?
| | Protein Binding | 3 | 2024 | 665 | 0.140 |
Why?
| | Adenosine Triphosphate | 3 | 2024 | 233 | 0.140 |
Why?
| | Cytoplasmic Granules | 1 | 2016 | 25 | 0.140 |
Why?
| | Insulin | 2 | 2010 | 456 | 0.140 |
Why?
| | Macaca | 2 | 2006 | 7 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 2 | 2006 | 160 | 0.120 |
Why?
| | Blotting, Western | 3 | 2010 | 601 | 0.120 |
Why?
| | Protein Biosynthesis | 1 | 2016 | 254 | 0.120 |
Why?
| | Gene Knockout Techniques | 1 | 2013 | 40 | 0.110 |
Why?
| | Integrases | 1 | 2013 | 43 | 0.110 |
Why?
| | Binding Sites | 2 | 2024 | 375 | 0.110 |
Why?
| | Genetic Engineering | 1 | 2013 | 24 | 0.110 |
Why?
| | Organ Specificity | 1 | 2013 | 108 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2016 | 1108 | 0.110 |
Why?
| | Mutation | 2 | 2024 | 1294 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 1586 | 0.100 |
Why?
| | Racemases and Epimerases | 1 | 2012 | 15 | 0.100 |
Why?
| | Serine | 1 | 2012 | 37 | 0.100 |
Why?
| | Rats | 3 | 2019 | 3299 | 0.100 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2012 | 40 | 0.100 |
Why?
| | Overnutrition | 1 | 2011 | 10 | 0.090 |
Why?
| | Gene Expression | 1 | 2013 | 609 | 0.090 |
Why?
| | HeLa Cells | 2 | 2016 | 260 | 0.090 |
Why?
| | Enteral Nutrition | 1 | 2011 | 147 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2010 | 978 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 2011 | 175 | 0.090 |
Why?
| | Fatty Liver | 1 | 2011 | 127 | 0.080 |
Why?
| | Weight Gain | 1 | 2011 | 239 | 0.080 |
Why?
| | Recombinant Proteins | 2 | 2021 | 487 | 0.080 |
Why?
| | Overweight | 1 | 2010 | 217 | 0.070 |
Why?
| | Age Factors | 1 | 2011 | 1092 | 0.070 |
Why?
| | Health | 1 | 2007 | 23 | 0.070 |
Why?
| | Disease Progression | 2 | 2012 | 831 | 0.070 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 3 | 0.070 |
Why?
| | Cyclooxygenase 1 | 1 | 2006 | 5 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2006 | 5 | 0.070 |
Why?
| | Prostaglandin D2 | 1 | 2006 | 21 | 0.070 |
Why?
| | Leukotrienes | 1 | 2006 | 9 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2006 | 45 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2006 | 113 | 0.070 |
Why?
| | Cell Line | 2 | 2010 | 1021 | 0.070 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 17 | 0.070 |
Why?
| | Prostaglandins | 1 | 2005 | 20 | 0.070 |
Why?
| | Prediabetic State | 1 | 2005 | 19 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2005 | 96 | 0.060 |
Why?
| | Mice, Inbred BALB C | 4 | 2006 | 305 | 0.060 |
Why?
| | Liver | 2 | 2010 | 1116 | 0.060 |
Why?
| | Vasodilation | 1 | 2005 | 96 | 0.060 |
Why?
| | Pneumonia | 1 | 2006 | 118 | 0.060 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 2 | 0.060 |
Why?
| | Sp3 Transcription Factor | 1 | 2004 | 5 | 0.060 |
Why?
| | Free Radicals | 1 | 2004 | 28 | 0.060 |
Why?
| | Drosophila | 1 | 2004 | 17 | 0.060 |
Why?
| | Down-Regulation | 1 | 2006 | 349 | 0.060 |
Why?
| | Blotting, Northern | 1 | 2004 | 109 | 0.060 |
Why?
| | Luciferases | 1 | 2004 | 50 | 0.060 |
Why?
| | Ethanol | 1 | 2007 | 341 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2006 | 207 | 0.060 |
Why?
| | Models, Chemical | 1 | 2004 | 64 | 0.060 |
Why?
| | Fibroblasts | 2 | 2007 | 351 | 0.060 |
Why?
| | Hydrolysis | 1 | 2024 | 62 | 0.060 |
Why?
| | Acetylcysteine | 1 | 2004 | 100 | 0.060 |
Why?
| | Plasmids | 1 | 2004 | 161 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2024 | 148 | 0.060 |
Why?
| | Male | 7 | 2019 | 25399 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 320 | 0.060 |
Why?
| | Genomic Instability | 1 | 2024 | 93 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 254 | 0.060 |
Why?
| | Transfection | 1 | 2004 | 355 | 0.060 |
Why?
| | DNA Replication | 1 | 2024 | 150 | 0.050 |
Why?
| | Mice | 6 | 2012 | 5759 | 0.050 |
Why?
| | Models, Molecular | 1 | 2024 | 341 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2005 | 201 | 0.050 |
Why?
| | Isoquinolines | 1 | 2002 | 28 | 0.050 |
Why?
| | NAD | 1 | 2002 | 43 | 0.050 |
Why?
| | Asthma | 1 | 2006 | 280 | 0.050 |
Why?
| | Benzamides | 1 | 2002 | 51 | 0.050 |
Why?
| | Streptavidin | 1 | 2021 | 16 | 0.050 |
Why?
| | Inflammation | 1 | 2006 | 604 | 0.050 |
Why?
| | Phase Transition | 1 | 2021 | 6 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2004 | 650 | 0.050 |
Why?
| | Cell Division | 1 | 2002 | 295 | 0.050 |
Why?
| | Guanine | 1 | 2021 | 40 | 0.050 |
Why?
| | Catalysis | 1 | 2021 | 88 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2021 | 36 | 0.050 |
Why?
| | Substrate Specificity | 1 | 2021 | 193 | 0.050 |
Why?
| | Repressor Proteins | 1 | 2021 | 153 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2021 | 275 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2004 | 1416 | 0.040 |
Why?
| | Organ Culture Techniques | 1 | 2019 | 48 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 81 | 0.040 |
Why?
| | Cytokines | 3 | 2006 | 613 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2002 | 1581 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 475 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2021 | 376 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2019 | 327 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2019 | 231 | 0.040 |
Why?
| | Kinetics | 1 | 2019 | 631 | 0.040 |
Why?
| | Ovalbumin | 2 | 2006 | 18 | 0.030 |
Why?
| | Th2 Cells | 2 | 2006 | 21 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 40 | 0.030 |
Why?
| | Allergens | 2 | 2006 | 140 | 0.030 |
Why?
| | Female | 5 | 2012 | 26635 | 0.020 |
Why?
| | Resistin | 1 | 2010 | 6 | 0.020 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2010 | 13 | 0.020 |
Why?
| | Adenylate Kinase | 1 | 2010 | 10 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 550 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2010 | 59 | 0.020 |
Why?
| | Microglia | 1 | 2012 | 140 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 453 | 0.020 |
Why?
| | Fibroblast Growth Factors | 1 | 2010 | 47 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 244 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2012 | 846 | 0.020 |
Why?
| | Leptin | 1 | 2010 | 140 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 595 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2010 | 185 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2007 | 1 | 0.020 |
Why?
| | Endothelium | 1 | 2007 | 39 | 0.020 |
Why?
| | Hypertrophy | 1 | 2007 | 50 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2007 | 57 | 0.020 |
Why?
| | Protein Kinases | 1 | 2007 | 71 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2007 | 56 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 140 | 0.020 |
Why?
| | Nigella sativa | 1 | 2006 | 1 | 0.020 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2006 | 4 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2007 | 113 | 0.020 |
Why?
| | Dinoprostone | 1 | 2006 | 53 | 0.020 |
Why?
| | Goblet Cells | 1 | 2006 | 2 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2006 | 72 | 0.020 |
Why?
| | Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2005 | 1 | 0.020 |
Why?
| | Acetophenones | 1 | 2005 | 11 | 0.020 |
Why?
| | Onium Compounds | 1 | 2005 | 13 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 2006 | 92 | 0.020 |
Why?
| | Acetylcholine | 1 | 2005 | 54 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 26 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2005 | 39 | 0.020 |
Why?
| | Collagen | 1 | 2007 | 207 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2005 | 96 | 0.020 |
Why?
| | Tyrosine | 1 | 2005 | 95 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2006 | 186 | 0.020 |
Why?
| | Hypersensitivity | 1 | 2006 | 77 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2007 | 270 | 0.020 |
Why?
| | Aorta | 1 | 2005 | 162 | 0.010 |
Why?
| | Homeostasis | 1 | 2005 | 201 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 254 | 0.010 |
Why?
| | Diet | 1 | 2007 | 557 | 0.010 |
Why?
| | Pregnancy | 1 | 2010 | 2604 | 0.010 |
Why?
| | Apoptosis | 1 | 2007 | 1112 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 979 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 1622 | 0.010 |
Why?
|
|
Marecki's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|